Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Curran

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Cancer Journal|April 3, 2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trialFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
American Journal of Hematology|July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMAFieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Cancer Journal|April 3, 2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trialFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
American Journal of Hematology|July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMAFieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.
Pageof 10